Cargando…
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
BACKGROUND: Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosuppressive tumor microenvironment (TME) which limits the activity of tumor-infiltr...
Autores principales: | Harrasser, Micaela, Gohil, Satyen Harish, Lau, Hiu, Della Peruta, Marco, Muczynski, Vincent, Patel, Dominic, Miranda, Elena, Grigoriadis, Kristiana, Grigoriadis, Anita, Granger, David, Evans, Rachel, Nathwani, Amit Chunilal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166313/ https://www.ncbi.nlm.nih.gov/pubmed/35659040 http://dx.doi.org/10.1186/s13058-022-01531-1 |
Ejemplares similares
-
An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors
por: Gohil, Satyen Harish, et al.
Publicado: (2017) -
Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug
por: Bemani, Peyman, et al.
Publicado: (2018) -
Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
por: Shams, Nasir, et al.
Publicado: (2022) -
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020) -
scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012)